LQAI0.260%
as of Sep 2
BSX
GrowthBOSTON SCIENTIFIC CORPORATION
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular.
Close · 3M
-24.36%
Held by 1 AI ETF
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals12
Win rate67% (8/12)
Avg buy return+0.92%
LQAI · New entry · 1d
weight 0 → 0.260% (new)·stock up 10.0% in the 30 days before
Aug 6·entry $49.30·now $46.95Fresh
-4.77%
since Aug 6
PQUS · Exit · 1d
weight 0.370% → 0 (exited)·stock up 16.2% in the 30 days before
Aug 14·entry $51.83·now $46.95
-9.42%
since Aug 14
PQUS · Weight increase · 2d
weight 0.350% → 0.370% (+0.020 pp)·stock up 20.1% in the 30 days before
Aug 13·entry $51.69·now $46.95Fresh
-9.17%
since Aug 13
PQUS · Weight decrease · 2d
weight 1.050% → 0.350% (-0.700 pp)·stock up 9.6% in the 30 days before
Aug 8·entry $50.46·now $46.95
-6.96%
since Aug 8
PQUS · Sudden change · 1d
weight 1.050% → 0.360% (-0.690 pp)·stock up 9.6% in the 30 days before
Aug 7·entry $49.31·now $46.95
-4.79%
since Aug 7
PQUS · Weight increase · 2d
weight 0.990% → 1.040% (+0.050 pp)·stock up 8.5% in the 30 days before
Jul 31·entry $46.73·now $46.95Fresh
+0.47%
since Jul 31
PQUS · Weight decrease · 2d
weight 1.030% → 1.000% (-0.030 pp)·stock down 0.5% in the 30 days before
Jul 24·entry $44.25·now $46.95
+6.10%
since Jul 24
PQUS · Weight increase · 2d
weight 0.910% → 1.030% (+0.120 pp)·stock down 6.2% in the 30 days before
Jul 18·entry $43.77·now $46.95Drifting
+7.27%
since Jul 18
PQUS · Weight decrease · 2d
weight 0.970% → 0.950% (-0.020 pp)·stock down 8.6% in the 30 days before
Jul 12·entry $44.65·now $46.95
+5.15%
since Jul 12
PQUS · Weight increase · 2d
weight 0.910% → 0.970% (+0.060 pp)·stock down 8.6% in the 30 days before
Jul 10·entry $44.77·now $46.95Drifting
+4.87%
since Jul 10
PQUS · Weight decrease · 2d
weight 0.940% → 0.870% (-0.070 pp)·stock down 5.3% in the 30 days before
Jul 2·entry $45.14·now $46.95
+4.01%
since Jul 2
PQUS · Weight decrease · 2d
weight 0.970% → 0.940% (-0.030 pp)·stock down 12.3% in the 30 days before
Jun 27·entry $43.48·now $46.95
+7.98%
since Jun 27
+0.41%
since Jun 14
-3.59%
since Jun 7
AIVL · Exit · 1d
weight 0.216% → 0 (exited)·stock up 8.5% in the 30 days before
Jul 31·entry $46.73·now $46.95
+0.47%
since Jul 31
AIVL · Weight increase · 4d
weight 0.204% → 0.216% (+0.012 pp)·stock up 5.9% in the 30 days before
Jul 29·entry $46.04·now $46.95Fresh
+1.98%
since Jul 29
AIVL · Weight increase · 3d
weight 0.204% → 0.213% (+0.009 pp)·stock up 4.1% in the 30 days before
Jul 28·entry $46.06·now $46.95Fresh
+1.93%
since Jul 28
AIVL · Weight increase · 2d
weight 0.204% → 0.208% (+0.004 pp)·stock down 0.5% in the 30 days before
Jul 24·entry $44.25·now $46.95Drifting
+6.10%
since Jul 24
AIVL · Weight decrease · 2d
weight 0.207% → 0.204% (-0.003 pp)·stock down 3.1% in the 30 days before
Jul 22·entry $42.97·now $46.95
+9.26%
since Jul 22
AIVL · Weight increase · 2d
weight 0.203% → 0.209% (+0.006 pp)·stock down 4.6% in the 30 days before
Jul 16·entry $44.62·now $46.95Drifting
+5.22%
since Jul 16
AIVL · Weight increase · 2d
weight 0.202% → 0.213% (+0.011 pp)·stock down 5.3% in the 30 days before
Jul 2·entry $45.14·now $46.95Drifting
+4.01%
since Jul 2
+6.22%
since Jun 25
+5.91%
since Jun 22
+3.67%
since Jun 18
+0.06%
since Jun 16
+0.09%
since Jun 12
-0.47%
since Jun 11
-3.30%
since Jun 5
-1.55%
since Jun 3
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.
Buffett-style framework
Fails the frameworkas of Jul 19
AI ETFs PQUS and AIVL show recent increasing trends in their holdings of Boston Scientific, suggesting an accumulation or positive sentiment toward the stock. This contrasts with the framework's 'Fail' verdict, which is driven by a lack of sufficient financial transparency and an absent margin of safety from the available data.
- Circle of CompetenceBoston Scientific operates in the health care equipment industry, which typically has predictable demand and unit economics, allowing for reasonable projection of cash flows.
- Economic MoatThe company benefits from significant switching costs for medical professionals, a strong intellectual property portfolio, and regulatory barriers to entry, creating a durable economic moat.
- ManagementThe provided data is insufficient to evaluate management's candor, capital allocation discipline, or skin in the game.
- Financial HealthThe provided financials are insufficient to assess the 10-year average ROE, stability of operating margins, debt manageability, or owner earnings, and the single ROE point is just below the preferred threshold.
- Margin of SafetyBased on the provided valuation multiples (PER, PBR, EV/EBITDA), there is no clear indication of a defensible discount to intrinsic value or a significant margin of safety.
Boston Scientific operates in a comprehensible area with a clear economic moat, passing initial framework stages. However, a significant lack of comprehensive financial data prevents a full assessment of its financial health and owner earnings. Furthermore, the current valuation multiples do not suggest a margin of safety, leading to an overall 'Fail' verdict.
Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.